[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334281-105":3,"doc-detail-334281-en":81,"detail-sidebar-cat-0-en-105":98},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","whole-exome-seq-and-rna-seq-data-reveal-unique-neoantigen-profiles-in-kenyan-breast-cancer-patients","Whole exome-seq and RNA-seq data reveal unique neoantigen proﬁles in Kenyan breast cancer patients","","Whole-exome sequencing (WES) and total RNA sequencing (RNA-seq) were used to profile neoantigens in Kenyan breast cancer patients by analyzing paired tumor and adjacent non-cancer tissues from 23 individuals. Somatic mutations were identified from WES and expression was quantified from RNA-seq to predict neoantigens across HLA class I (HLA type I) alleles. Neoantigens were considered potentially immunogenic based on predicted median IC50 binding scores and tumor expression thresholds, revealing patient-specific neoantigen profiles linked to somatic mutation patterns.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/whole-exome-seq-and-rna-seq-data-reveal-unique-neoantigen-profiles-in-kenyan-breast-cancer-patients/334281/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/whole-exome-seq-and-rna-seq-data-reveal-unique-neoantigen-profiles-in-kenyan-breast-cancer-patients/334281.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main objective?","Question",{"text":63,"@type":64},"To profile neoantigens in Kenyan breast cancer patients using genomic DNA and total RNA from paired tumor and adjacent non-cancer tissue samples.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were neoantigens classified as potentially immunogenic?",{"text":68,"@type":64},"Neoantigen predictions were evaluated using HLA class I considerations, with immunogenic candidates defined by predicted median IC50 binding scores and expression levels in tumor samples.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationship did the results show between neoantigens and somatic mutations?",{"text":72,"@type":64},"The presence of neoantigens significantly correlated with somatic mutations, indicating that patient-specific mutation patterns contribute to the observed neoantigen profiles.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334281,1790013122,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":86,"file_id":87,"file_url":88,"file_type":89,"file_size":90,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":91,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Original Research PUBLISHED 11 December 2024 DOI 10.3389/fonc.2024.1444327  \nOPEN ACCESS  \nEDITED BY  \nZodwa Dlamini,  \nPan African Cancer Research Institute (PACRI), South Africa  \nREVIEWED BY  \nSambhavi Animesh,  \nMassachusetts General Hospital and Harvard Medical School, United States  \nSerge The´ophille Soubeiga,  \nResearch Institute for Health Sciences (IRSS), Burkina Faso  \n*CORRESPONDENCE  \nFrancis Makokha  \n [fmakokha@mku.ac.ke](fmakokha@mku.ac.ke)  \nRECEIVED 05 June 2024  \nACCEPTED 25 November 2024  \nPUBLISHED 11 December 2024  \nCITATION  \nWagutu G, Gitau J, Mwangi K, Murithi M, Melly E, Harris AR, Sayed S, Ambs S and Makokha F (2024) Whole exome-seq and RNA-seq data reveal unique neoantigen proﬁles in Kenyan breast cancer patients. Front. Oncol. 14:1444327 .  \ndoi: 10.3389/fonc.2024.1444327  \nCOPYRIGHT  \n© 2024 Wagutu, Gitau, Mwangi, Murithi, Melly, Harris, Sayed, Ambs and Makokha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nWhole exome-seq and RNA-seq data reveal unique neoantigen proﬁles in Kenyan breast cancer patients  \nGodfrey Wagutu 1, John Gitau 1,2,3, Kennedy Mwangi 4,  \nMary Murithi 5, Elias Melly 6, Alexandra R. Harris 7, Shahin Sayed 8, Stefan Ambs 7 and Francis Makokha 1*  \n1 Directorate of Research and Innovation, Mount Kenya University, Thika, Kenya, 2African Institute for Mathematical Science, Kigali, Rwanda, 3Center for Epidemiological Modeling and Analysis,  \nNairobi, Kenya, 4 International Livestock Research Institute, Nairobi, Kenya, 5 Department of PreClinical, Kabarak University, Nakuru, Kenya, 6 National Cancer Institute, Nairobi, Kenya, 7 Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, MD, United States, 8Aga Khan University Hospital, Nairobi, Kenya  \nBackground: The immune response against tumors relies on distinguishing between self and non-self, the basis of cancer immunotherapy. Neoantigens from somatic mutations are central to many immunotherapeutic strategies and understanding their landscape in breast cancer is crucial for targeted interventions. We aimed to proﬁle neoantigens in Kenyan breast cancer patients using genomic DNA and total RNA from paired tumor and adjacent non-cancerous tissue samples of 23 patients.  \nMethods: We sequenced the genome-wide exome (WES) and RNA, from which somatic mutations were identiﬁed and their expression quantiﬁed, respectively. Neoantigen prediction focused on human leukocyte antigens (HLA) crucial to cancer, HLA type I. HLA alleles were predicted from WES data covering the adjacent non-cancerous tissue samples, identifying four alleles that were present in at least 50% of the patients . Neoantigens were deemed potentially immunogen ic if their predicted median IC50 (half-maximal inhibitory concentration) binding scores were ≤500nM and were expressed [transcripts per million (TPM) >1] in tumor samples.  \nResults: An average of 1465 neoantigens covering 10260 genes had ≤500nM median IC50 binding score and >1 TPM in the 23 patients and their presence signiﬁcantly correlated with the somatic mutations (R2 = 0 . 570, P=0 . 001) . Assessing 58 genes reported in the catalog of somatic mutations in cancer (COSMIC, v99) to be commonly mutated in breast cancer, 44 (76%) produced >2 neoantigens among the 23 patients, with a mean of 10 . 5 ranging from 2 to 93 . For the 44 genes, a total of 477 putative neoantigens were identiﬁed, predominantly derived from missense mutations (88%), indels (6%), and frameshift mutations (6%) . Notably, 78% of the putative breast cancer neoantigens were patientspeciﬁc. HLA-C*06:01 allele was associate","cbCaiu1u0ua29BiR","https://ap.wps.com/l/cbCaiu1u0ua29BiR","pdf",6637904,11,"English","# Background\n## Immune response, neoantigens, and immunotherapy rationale\n# Methods\n## WES/RNA-seq workflow and neoantigen prediction criteria\n# Results\n## Neoantigen counts, HLA associations, and gene-level findings\n# Conclusions","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To profile neoantigens in Kenyan breast cancer patients using genomic DNA and total RNA from paired tumor and adjacent non-cancer tissue samples.\"},{\"question\":\"How were neoantigens classified as potentially immunogenic?\",\"answer\":\"Neoantigen predictions were evaluated using HLA class I considerations, with immunogenic candidates defined by predicted median IC50 binding scores and expression levels in tumor samples.\"},{\"question\":\"What relationship did the results show between neoantigens and somatic mutations?\",\"answer\":\"The presence of neoantigens significantly correlated with somatic mutations, indicating that patient-specific mutation patterns contribute to the observed neoantigen profiles.\"}]","Whole exome-seq and RNA-seq data reveal unique neoantigen proﬁles in Kenyan breast cancer patients | PDF",1790006112,28,{"code":4,"msg":82,"data":99},[100,104,108,112,117,122,127,130,135,138,142],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":105,"show_sort_weight":106,"slug":107},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},"Exam",70,"exam",{"id":113,"doc_module":4,"doc_module_name":25,"category_name":114,"show_sort_weight":115,"slug":116},5,"Comic",60,"comic",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},6,"Technology",50,"technology",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":125,"slug":126},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":128,"slug":129},30,"research-report",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},9,"Religion & Spirituality",20,"religion-spirituality",{"id":133,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":133,"slug":137},"World Cup","world-cup",{"id":139,"doc_module":4,"doc_module_name":25,"category_name":140,"show_sort_weight":139,"slug":141},10,"Lifestyle","lifestyle",{"id":143,"doc_module":4,"doc_module_name":25,"category_name":144,"show_sort_weight":113,"slug":145},19,"General","general"]